Pluri Inc. Interest Expense
Pluri Inc. (PLUR) reported Interest Expense of $218.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-05-09
- Pluri Inc. interest expense for the quarter ending 2024-03-31 was $218.00K, a 0.46% increase year-over-year.
- Pluri Inc. interest expense for the quarter ending 2023-12-31 was $216.00K, a 1.89% increase year-over-year.
- Pluri Inc. interest expense for the quarter ending 2023-09-30 was $214.00K, a 10.31% increase year-over-year.
- Pluri Inc. interest expense for the quarter ending 2023-06-30 was $220.00K.
- Pluri Inc. interest expense for fiscal 2023 was $843.00K, a 4.96% decline from fiscal 2022.
- Pluri Inc. interest expense for fiscal 2022 was $887.00K, a 1037.18% increase from fiscal 2021.
- Pluri Inc. interest expense for fiscal 2021 was $78.00K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $218.00K 10-Q · filed 2024-05-09 | $434.00K derived: sum of 2 quarters · filed 2024-05-09 | $648.00K 10-Q · filed 2024-05-09 | $868.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | $216.00K 10-Q · filed 2024-02-12 | $430.00K 10-Q · filed 2024-02-12 | $650.00K derived: sum of 3 quarters · filed 2024-02-12 | $867.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-09-30 | $214.00K 10-Q · filed 2023-11-13 | $434.00K derived: sum of 2 quarters · filed 2023-11-13 | $651.00K derived: sum of 3 quarters · filed 2024-05-09 | $863.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-06-30 | $220.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-12 | $437.00K derived: sum of 2 quarters · filed 2024-05-09 | $649.00K derived: sum of 3 quarters · filed 2024-05-09 | $843.00K 10-K · filed 2023-09-12 |
| 2023-03-31 | $217.00K 10-Q · filed 2024-05-09 | $429.00K derived: sum of 2 quarters · filed 2024-05-09 | $623.00K 10-Q · filed 2024-05-09 | |
| 2022-12-31 | $212.00K 10-Q · filed 2024-02-12 | $406.00K 10-Q · filed 2024-02-12 | ||
| 2022-09-30 | $194.00K 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $887.00K 10-K · filed 2023-09-12 | |||
| 2021-06-30 | $78.00K 10-K · filed 2022-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |